Sciele Pharma, Inc. - Statement of Ownership: Solicitation (SC 14D9)
03 9월 2008 - 5:58AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Rule 14d-101)
Solicitation/Recommendation Statement Under
Section 14(d)(4) of the Securities Exchange Act of 1934
SCIELE PHARMA, INC.
(Name of Subject Company)
SCIELE PHARMA,
INC.
(Name of Person(s) Filing
Statement)
Common Stock,
$0.001 par value per share
(Title or Class of
Securities)
808627103
(CUSIP Number of Class of
Securities)
Patrick P.
Fourteau
Chief Executive Officer
Sciele Pharma, Inc.
5 Concourse Parkway, Suite 1800
Atlanta, Georgia 30328
(770) 442 9707
(Name, address and telephone number of person authorized
to receive notices and communications on behalf of the person(s) filing statement)
With Copies to:
W. Tinley
Anderson, III, Esq.
Paul, Hastings, Janofsky & Walker LLP
600 Peachtree St., N. E., Suite 2400
Atlanta, GA 30308
(404) 815-2400
x
Check
the box if the filing relates solely to preliminary communications made before the
commencement of a tender offer.
This
Schedule 14D-9 contains the following exhibits:
Exhibit A
Exhibit A
is a joint press release, dated September 1, 2008, relating to the
proposed acquisition of Sciele Pharma, Inc. by Shionogi & Co., Ltd.
Exhibit B
Exhibit B is a script of a presentation to analysts
made on September 2, 2008.
1
Sciele Pharma (MM) (NASDAQ:SCRX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Sciele Pharma (MM) (NASDAQ:SCRX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024